| Literature DB >> 26539517 |
Md Ibrahim Khalil1, Istiyak Ahmmed2, Romana Ahmed2, E M Tanvir2, Rizwana Afroz2, Sudip Paul2, Siew Hua Gan3, Nadia Alam3.
Abstract
We investigated the protective role of Withania somnifera leaf extract (WSLEt) on isoproterenol- (ISO-) induced myocardial infarction (MI) in rats. Subcutaneous injection of ISO (85 mg/kg body weight (b.w.)) administered to rats for two consecutive days caused a significant increase in cardiac troponin I (cTnI) levels and serum lipid profiles, as well as the activities of some marker enzymes. In addition to these diagnostic markers, there were increased levels of lipid peroxidation (LPO) and decreased activities of enzymatic antioxidants (superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase (GRx), and glutathione-S-transferase (GST)) in the myocardium. However, oral pretreatment (100 mg/kg b.w.) with WSLEt for 4 weeks elicited a significant cardioprotective activity by lowering the levels of cTnI, lipid profiles, and marker enzymes. The levels of LPO products were also significantly decreased. Elevated activities of antioxidant enzymes were also observed in rats pretreated with WSLEt. As further confirmed histopathologically, our findings strongly suggest that the cardioprotective effect of WSLEt on myocardium experiencing ISO-induced oxidative damage may be due to an augmentation of the endogenous antioxidant system and an inhibition of LPO in the myocardial membrane. We conclude that WSLEt confers some protection against oxidative damage in ISO-induced MI in rats.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26539517 PMCID: PMC4619872 DOI: 10.1155/2015/624159
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Schematic representation of experimental design of the study.
Changes in the body and heart weights in different groups of rats.
| Parameters | Group | |||
|---|---|---|---|---|
| Sham | WSLEt + Sham | WSLEt + ISO | ISO | |
| Initial body weight (g) | 143.70 ± 24.16a | 146.71 ± 15.99a | 141.00 ± 23.43a | 148.63 ± 19.91a |
| Final body weight (g) | 164.82 ± 19.28a | 175.00 ± 6.36a | 169.75 ± 16.64a | 172.00 ± 21.59a |
| Body weight gain (g) | 21.12a | 28.29a | 28.75a | 23.37a |
| Absolute heart weight (g) | 0.62 ± 0.03a | 0.66 ± 0.03a | 0.73 ± 0.02b | 0.97 ± 0.06c |
| Relative heart weight (g/100 g) | 0.39 ± 0.02a | 0.39 ± 0.01a | 0.49 ± 0.02b | 0.57 ± 0.04c |
Results are expressed as mean values ± SD; n = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at p < 0.05.
Figure 2WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in cTnI levels. Bars represent mean values ± SD (n = 10); bars with different letters represent significantly different mean values at p < 0.05. ND: not detected.
Figure 3WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in the cardiac marker enzyme activities. (a) The effects of WSLEt on CK-MB and LDH levels and (b) the effects of WSLEt on AST and ALT levels. Bars represent mean values ± SD (n = 10); bars with different letters represent significantly different mean values at p < 0.05.
WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in the serum lipid profiles.
| Parameters | Group | |||
|---|---|---|---|---|
| Sham | WSLEt + Sham | WSLEt + ISO | ISO | |
| TC (mg/dL) | 50.19 ± 6.34a | 45.67 ± 4.93a | 56.37 ± 6.38b | 74.75 ± 12.35c |
| TG (mg/dL) | 42.69 ± 5.55a | 38.46 ± 8.09a | 67.56 ± 8.90b | 82.29 ± 6.12c |
| VLDL-C (mg/dL) | 8.54 ± 1.11a | 7.69 ± 1.39a | 12.33 ± 1.41b | 16.46 ± 1.22c |
| HDL-C (mg/dL) | 45.12 ± 2.71a | 49.12 ± 4.49b | 46.04 ± 1.15ab | 19.89 ± 1.21c |
Results are expressed as mean values ± SD; n = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at p < 0.05.
WSLEt ameliorates the oxidative damage caused by ISO as demonstrated by the changes in LPO levels and the activities of SOD, GRx, GPx, and GST.
| Parameters | Group | |||
|---|---|---|---|---|
| Sham | WSLEt + Sham | WSLEt + ISO | ISO | |
| LPO (nmol TBARS/mg of protein) | 42.77 ± 1.05a | 37.18 ± 1.85a | 40.02 ± 1.17a | 82.17 ± 1.35b |
| SOD (units/mg of protein) | 1.45 ± 0.02ab | 1.58 ± 0.16a | 0.33 ± 0.02b | 0.10 ± 0.00c |
| GRx (nmol NADPH oxidized/min/mg of protein) | 97.56 ± 2.09a | 90.57 ± 1.79a | 97.14 ± 6.05a | 75.59 ± 9.79b |
| GPx (nmol NADPH oxidized/min/mg of protein) | 2.15 ± 0.45a | 3.12 ± 0.16b | 1.98 ± 0.00ab | 0.96 ± 0.00c |
| GST (nmol of CDNB conjugated/min/mg of protein) | 2.04 ± 0.06a | 4.05 ± 0.19b | 1.99 ± 0.11a | 0.85 ± 0.02c |
Results are expressed as mean values ± SD; n = 10. a,b,cValues in the same row that do not share superscript letters (a, b, c) differ significantly at p < 0.05.
Figure 4(a) Sham group: normal control heart showing normal cardiac muscle fibers. (b) WSLEt + Sham group: WSLEt-treated (100 mg/kg) heart showing normal muscle fibers without any pathological changes. (c) WSLEt + ISO group: WSLEt-treated (100 mg/kg) + ISO-treated (85 mg/kg) heart showing no edematous intramuscular space and fewer inflammatory cells (black arrows). (d) ISO group: ISO-treated (85 mg/kg) heart showing cardiac muscle fibers with muscle separation (green arrows), edematous intramuscular space (red arrows), and inflammatory cells (black arrows).